Es Short Stature High Risk Screen

---
name: es-short-stature-high-risk-screen
description: This skill identifies childhood cancer survivors at high risk for short adult height based on cranial/spinal/total body irradiation at a young age or a history of inadequate weight gain or prolonged steroid requirement. It is triggered by questions such as "Does this survivor need growth monitoring?" or "Is this patient high-risk for growth impairment?"
---

# Identify high-risk patients for short adult height in childhood cancer survivors

## STEP 1 — Gather Information
Collect age at cancer treatment, type and dose of radiation (cranial RT, craniospinal irradiation, total body irradiation), weight gain trajectory, and duration of steroid therapy.

## STEP 2 — Rule In / Rule Out
Determine if the survivor received cranial radiation therapy, craniospinal irradiation, or total body irradiation at a young age **or** has a history of inadequate weight gain or prolonged steroid requirement. If yes, rule in as high risk; otherwise, rule out.

## STEP 3 — Classify or Stratify
Classify the patient as high risk for short adult height when any of the above criteria are met.

## STEP 4 — Decide
If high risk, initiate prospective linear growth follow‑up: measure standing height every 6–12 months and obtain sitting height if spinal radiation was given. If not high risk, follow routine survivorship care without additional growth monitoring.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on serum IGF‑I levels to exclude risk; do not overlook spinal radiation as a cause of disproportionate short stature; consider mimics such as malnutrition, hypothyroidism, or glucocorticoid excess; avoid assuming normal current height excludes future risk because growth failure may be delayed.

## Concrete Clinical Example
An 8‑year‑old survivor of medulloblastoma who received craniospinal irradiation 24 Gy at age 4 presents with normal height but reports poor weight gain; the history of spinal radiation at a young age rules in high risk, prompting enrollment in semi‑annual height measurements.

**Source:** Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-01175